Table 5.
MINORS quality assessment
| Authors | Total points | Clearly stated aim | Inclusion of consecutive patients | Prospective collection of data | Appropriate endpoints | Unbiased assessment | Follow-up appropriate | Loss of follow-up < 5% | Sample size calculation | Control group | Contemporary groups | Baseline group equivalence | Adequate statistical analysis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sokkar [19] | 7 | 0 | 2 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Cai [20] | 17 | 2 | 2 | 2 | 2 | 0 | 1 | 2 | 0 | 0 | 2 | 2 | 2 |
| Pongsamakthai and Tharakulphan [21] | 19 | 2 | 2 | 2 | 2 | 0 | 1 | 2 | 2 | 0 | 2 | 2 | 2 |
| Stein [22] | 18 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 2 | 2 |
| Andreani [23] | 8 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 |
| Metzlaff [24] | 16 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 0 | 2 | 0 | 2 |
| Jensen[25] | 11 | 2 | 2 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 2 |
| Natero-Cisneros [26] | 10 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 2 |
| Razak [27] | 18 | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 2 | 0 | 2 | 2 | 2 |
| Taleb [28] | 11 | 2 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 2 |
|
Li 2020 |
12 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 2 |
| Fosser [30] | 12 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 2 |
| Shen [31] | 13 | 2 | 0 | 0 | 2 | 0 | 2 | 1 | 0 | 0 | 2 | 2 | 2 |
| Yoo [32] | 12 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 2 |
| Liu [33] | 10 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 2 |